The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients—results of a Nationwide Observational Study (PROSa)

Abstract

Background Sarcomas are rare cancers of high heterogeneity. Health-Related Quality of Life (HRQoL) has been shown to be a prognostic factor for survival in other cancer entities but it is unclear whether this applies to sarcoma patients. Patients and methods HRQoL was prospectively assessed in adult sarcoma patients from 2017 to 2020 in 39 German recruiting sites using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Vital status was ascertained over the course of 1 year. HRQoL domains were analysed by multivariable cox-regressions including clinical and socio-economic risk factors. Results Of 1102 patients, 126 (11.4%) died during follow-up. The hazard ratio (HR) for global health was 0.73 per 10-point increase (95% confidence interval (CI) 0.64–0.85). HR for the HRQoL-summary score was 0.74 (CI 0.64–0.85) and for physical functioning 0.82 (CI 0.74–0.89). There was also evidence that fatigue (HR 1.17, CI 1.10–1.25), appetite loss (HR 1.15, CI 1.09–1.21) and pain (HR 1.14, CI 1.08–1.20) are prognostic factors for survival. Conclusion Our study adds sarcoma-specific evidence to the existing data about cancer survival in general. Clinicians and care-givers should be aware of the relations between HRQoL and survival probability and include HRQoL in routine assessment.

Clinical Outcome SF-36 Score Following Above-Knee Amputation in Osteosarcoma Patients at H. Adam Malik Hospital Medan 2013 – 2018

“…(Hudson al., 1990;Bacci et al, 2000) A study showed that quality of life could be an independent prognostic factor for survival in osteosarcoma patients. (Eichler et al, 2022) In this study, the average physical and mental components were 49.76±14.33 and 49.01±14.67. Some studies use a score above 50 to be interpreted as a good quality of life and a score below 50 to be interpreted as poor quality of lif e. (Modersitzki et al, 2014) The average results obtained in this study are classified as poor results.…”

The Therapeutic Role of Plastic and Reconstructive Surgery in the Interdisciplinary Treatment of Soft-Tissue Sarcomas in Germany—Cross-Sectional Results of a Prospective Nationwide Observational Study (PROSa)

“…The PROSa study is one of the largest prospective observational studies in sarcoma patients published thus far [ 43 , 44 , 45 ]. Cases from 39 study centers encompassing hospitals of maximum care as well as community hospitals and private practices were included.…”

“…However, in analogy to the limited experience of primary and secondary healthcare providers with STSs, which can prolong diagnostic intervals and delay specialist referrals, plastic and reconstructive surgery services are not ubiquitously available [ 40 , 41 , 42 ]. The aim of this present analysis was therefore to evaluate the state of accessibility of microvascular reconstructive surgery as well as its role and potential impact on the quality of medical care amongst the participants of the prospective nationwide PROSa (patient-reported outcome measures in sarcoma patients treated between 1984 and 2019) cohort study, which was conducted between September 2017 and February 2019 in 39 German study centers (ClinicalTrials.gov Identifier: NCT03521531), the data from which have previously been published elsewhere [ 43 , 44 , 45 ].…”

Distress in soft‐tissue sarcoma and gastrointestinal stromal tumours patients—Results of a German multicentre observational study (PROSa)

“…We excluded individuals who were mentally or linguistically unable to complete questionnaires in German. Patients were recruited within the PROSa-cohort study (Burden and Medical Care of Sarcoma in Germany: Nationwide Cohort Study Focussing on Modifiable Determinants of Patient-Reported Outcome Measures in Sarcoma Patients), [16][17][18] that was conducted in 39 study sites between 2017 and 2020 (NCT03521531; ClinicalTrials.gov).…”